Beyond the CBC: Early Clues That Point to Hematologic Disease

May 04, 2026

Key Takeaways for Busy Providers

Persistent CBC abnormalities lasting more than 4-6 weeks (whether low or high counts) should prompt early collaboration with Moffitt hematology (a diagnosis is not needed).
Lymphoma red flags: adenopathy >4-6 weeks, B symptoms, elevated LDH, or mediastinal masses need timely specialist input.
MDS considerations: older adults with unexplained macrocytic anemia or persistent cytopenias benefit from early consultation.
Hypercoagulable disorders require hematology involvement when thrombosis occurs at a young age, is unprovoked, recurrent, or arises in atypical locations.
Protein abnormalities (elevated globulins, hypergammaglobulinemia) may indicate early myeloma, and these diagnoses are especially critical in Black patients.
MGUS Clinic: Moffitt’s MGUS Clinic provides dedicated, long-term surveillance for patients with Monoclonal gammopathy of undetermined significancePartner with Moffitt early when subtle clues arise. Early specialist collaboration significantly improves outcomes.
Patients with CBC abnormalities or other indications of hematologic disease can be referred to Moffitt for evaluation, no diagnosis necessary.

Primary care providers are the critical first line of detection for hematologic malignancies and serious pre-malignant conditions, where early recognition of signs and timely subspecialty consultation can dramatically improve patient outcomes. Recent research demonstrates that CBC patterns can predict hematologic malignancy risk with 84% accuracy within six months, yet many early warning signs remain subtle.

Moffitt's specialists partner with primary care physicians to enhance early detection capabilities, providing rapid access to advanced diagnostics and state-of-the-art therapies.

A primary care physician's proactive response to concerning blood test results and symptoms can significantly improve patients' fight against these cancers,

Medically reviewed by Rami Komrokji, MD, Vice Chair, Department of Malignant Hematology, Malignant Hematology Program.

Red Flag CBC Patterns That Demand Attention

Persistent Cytopenias

The most critical CBC warning signs involve persistent abnormalities lasting more than four to six weeks. Unexplained anemia affects 80-85% of patients with myelodysplastic syndrome (MDS), often presenting as macrocytic or normocytic anemia. When nutritional causes have been ruled out, persistent anemia (particularly in older adults) warrants a hematologic evaluation. Approximately one in six patients with unexplained anemia may have findings compatible with MDS.

Thrombocytopenia, neutropenia or anemia without clear etiology is another significant red flag for MDS, Acute Myeloid Leukemia (AML), or a precursor condition, especially when accompanied by abnormal platelet morphology indicating bone marrow dysfunction.

Elevated Blood Counts

While low counts grab attention, persistently elevated blood counts can be equally concerning. The following all call for closer investigation:

Lymphocytosis beyond typical recovery from viral illness
Unexplained leukocytosis
Persistent monocytosis

Abnormalities on White blood cell count differential namely observing circulating blasts or immature cells warrants hematological evaluation.

Our team focuses on alleviating symptoms, preventing serious complications, and improving the overall quality of life and survival for patients with all forms of MDS and AML.

David Sallman, MD

Myeloid Section Head, Moffitt Cancer Center

Beyond the CBC: Protein and Chemistry Clues

Elevated total protein or globulins may be the first laboratory clue to plasma cell disorders. Serum protein electrophoresis is a crucial screening tool for detecting monoclonal proteins that may indicate multiple myeloma or monoclonal gammopathy of undetermined significance (MGUS). Hypergammaglobulinemia, characterized by elevated immunoglobulin levels, can signal chronic lymphocytic leukemia, lymphoma or autoimmune conditions associated with hematologic malignancies.

These abnormalities are particularly significant in Black patients, who face higher myeloma incidence and often experience later-stage diagnosis.

"If you suspect your patient may have myeloma, it is important to refer them to a high-volume Mal Heme Program such as ours at Moffitt," adds Rachid Baz, MD, the Myeloma Section Head. Moffitt’s Multiple Myeloma program is dedicated to addressing the full spectrum of plasma cell disorders, including multiple myeloma and MGUS.

Elevated lactate dehydrogenase (LDH) levels can indicate increased cellular turnover and may suggest the presence of aggressive lymphoproliferative disorders. Hypercalcemia findings, especially when accompanied by bone pain or renal dysfunction, may signal multiple myeloma.

We need to start identifying people with MGUS so we can follow them. If they develop cancer, we can intervene literally when it turns from precancer to cancer, as opposed to waiting until it's too late.

Brandon Blue, MD

Moffitt’s Department of Malignant Hematology

Physical and Clinical Warning Signs

The overall incidence of malignancy in patients presenting to primary care with lymphadenopathy is 1.1%, so it’s rare, but careful evaluation is still essential. Lymphadenopathy that persists for longer than 4-6 weeks, especially when painless and rubbery, requires investigation. A patient presenting with palpable supraclavicular nodes of any size or epitrochlear nodes larger than 5 mm is considered abnormal and calls for closer attention.

Unexplained findings, including mediastinal masses or splenomegaly discovered on routine imaging, may represent the first indication of underlying hematologic malignancy such as lymphoma or leukemia before clinical symptoms develop.

B symptoms—fever exceeding 100.4°F, drenching night sweats requiring clothing changes, and weight loss exceeding 10% over six months—can indicate an aggressive form of lymphoma. About one-third of leukemia patients report drenching night sweats prior to diagnosis, often due to cytokine release and inflammatory response to malignancy.

Primary care physicians hold a crucial position in identifying the many indicators of lymphoma and initiating the necessary referral to specialists.

Javier Pinilla-Ibarz, MD, PhD

Lymphoma Section Head

Recurrent infections and hypercoagulability in young patients may also indicate underlying hematologic disease requiring specialist evaluation.

When to Contact Moffitt: Triggers for Consultation

A definitive diagnosis is not needed for a referral to Moffitt’s Malignant Hematology Program. Partnering with our specialists when early clues emerge allows us to quickly evaluate the patient and collaborate on the decision-making process.

A Moffitt consultation is available to patients who present with any of the following:

Suspicious lymphadenopathy that has persisted for several weeks
Pancytopenia
Persistent unexplained cytopenia
Leukopenia
Leukocytosis and thrombocytosis
Protein abnormalities
Clinical symptoms of plasma cell disorders, contact Moffitt.

A primary care physician's proactive response to concerning blood test results and symptoms can significantly improve patients' fight against these cancers. By working together, we can enhance early detection and treatment of hematologic malignancies, ultimately improving outcomes and survival rates.
Rachid Baz, MD, Myeloma Section Head, Moffitt Cancer Center

Partnership in Early Detection

Early consultation with Moffitt's specialists provides community providers access to subspecialty expertise while maintaining the primary care relationship. Your patient gains access to advanced diagnostics, molecular testing, staging, state-of-the-art therapies, including cellular therapies and stem cell transplant for select malignancies and treatment-resistant autoimmune disease, and you gain a partner in early detection.

Our team works collaboratively to determine optimal diagnostic approaches, helping interpret complex testing results and distinguish benign from worrisome patterns that warrant hematology evaluation. Together, we can develop individualized treatment plans that account for both disease factors and patient preferences. This partnership model ensures patients receive comprehensive care to improve their outcomes while keeping community providers involved throughout the treatment journey.

If you have a patient who has had persistent CBC abnormalities or other indications of hematologic disease, complete our online form to start the consultation process or contact a physician liaison for assistance. As part of our efforts to  shorten referral times as much as possible, online referrals are typically responded to within 24 - 48 hours.